Posts by Mourabit Halima

Hepatocellular carcinoma (HCC) is a common and highly lethal malignancy, with its treatment methods continuously evolving. In recent years, immunotherapy has become a hotspot in liver cancer treatment. Recently, Professor Zhexiong Lian's team from Southern Medical University published a paper in the Journal of Hepatology, revealing the potential value of inhibiting OXCT1 activity in tumor-associated macrophages (TAMs) for treating HCC. The study found that high OXCT1 expression is closely associated with poor prognosis in HCC patients. By inhibiting OXCT1, TAMs can be reprogrammed to an anti-tumor phenotype, enhancing the cytotoxicity of CD8+ T cells, thereby providing a new strategy for immunotherapy of liver cancer.

Diabetes and liver disease are common chronic diseases in China, with overlapping mechanisms, clinical manifestations, and therapeutic targets, making them interrelated risk factors. Co-managing these conditions can help reduce the disease burden. To support the development of diabetes and liver disease co-management in China, our publication, in collaboration with the China Diabetes and Liver Disease Co-management Action Plan (CDL), introduces the CDL Monthly Literature Review column. Each month, we will share research on the mechanisms, diagnosis, and treatment progress related to diabetes with liver disease, and invite experts from related fields in China to provide commentary. We aim to offer valuable insights and assistance to specialists, researchers, and frontline healthcare workers in conducting scientific research and clinical practice.

Antiviral therapy plays a crucial role in reducing the risk of liver cancer and delaying disease progression in patients with chronic hepatitis B (CHB). The survival rate and quality of life for CHB patients have been steadily improving. However, the treatment needs of "Small Three Yang" (HBsAg, anti-HBe, and anti-HBc positive) patients have often been overlooked. At the 17th National Clinical Conference on Liver Diseases held on May 25, 2024, Hepatology Digest interviewed the conference chairman, Professor Xiaoguang Dou from Shengjing Hospital of China Medical University, to discuss clinical cure strategies for "Small Three Yang" patients. Here is a summary of the interview for our readers.